|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singal AG and El-Serag HB: Hepatocellular
carcinoma from epidemiology to prevention: Translating knowledge
into practice. Clin Gastroenterol Hepatol. 13:2140–2151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mizuguchi Y, Takizawa T, Yoshida H and
Uchida E: Dysregulated miRNA in progression of hepatocellular
carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang RM, Xiao S, Lei X, Yang H, Fang F
and Yang LY: miRNA-487a promotes proliferation and metastasis in
hepatocellular carcinoma. Clin Cancer Res. 23:2593–2604. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dietrich P, Koch A, Fritz V, Hartmann A,
Bosserhoff AK and Hellerbrand C: Wild type Kirsten rat sarcoma is a
novel microRNA-622-regulated therapeutic target for hepatocellular
carcinoma and contributes to sorafenib resistance. Gut.
67:1328–1341. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kabir TD, Ganda C, Brown RM, Beveridge DJ,
Richardson KL, Chaturvedi V, Candy P, Epis M, Wintle L, Kalinowski
F, et al: A microRNA-7/growth arrest specific 6/TYRO3 axis
regulates the growth and invasiveness of sorafenib-resistant cells
in human hepatocellular carcinoma. Hepatology. 67:216–231. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang M, Zhang Q, Wang J and Zhai Y:
MicroRNA-498 is downregulated in non-small cell lung cancer and
correlates with tumor progression. J Cancer Res Ther. 11 Suppl
1:C107–C111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cong J, Liu R, Wang X, Wang J, Wang H and
Hou J: Low miR-498 expression levels are associated with poor
prognosis in ovarian cancer. Eur Rev Med Pharmacol Sci.
19:4762–4765. 2015.PubMed/NCBI
|
|
10
|
Islam F, Gopalan V, Law S, Tang JC, Chan
KW and Lam AK: MiR-498 in esophageal squamous cell carcinoma:
Clinicopathological impacts and functional interactions. Hum
Pathol. 62:141–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gopalan V, Smith RA and Lam AK:
Downregulation of microRNA-498 in colorectal cancers and its
cellular effects. Exp Cell Res. 330:423–428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kasiappan R, Shen Z, Tse AK, Jinwal U,
Tang J, Lungchukiet P, Sun Y, Kruk P, Nicosia SV, Zhang X, et al:
1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human
cancer growth through microRNA-498. J Biol Chem. 287:41297–41309.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu R, Liu F, Li L, Sun M and Chen K:
MiR-498 regulated FOXO3 expression and inhibited the proliferation
of human ovarian cancer cells. Biomed Pharmacother. 72:52–57. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kojima M, Sudo H, Kawauchi J, Takizawa S,
Kondou S, Nobumasa H and Ochiai A: MicroRNA markers for the
diagnosis of pancreatic and biliary-tract cancers. PLoS One.
10:e01182202015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC,
Qin LX, Wang L, Zhou J, Ren ZG, Li YX, et al: miR-612 suppresses
the invasive-metastatic cascade in hepatocellular carcinoma. J Exp
Med. 210:789–803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu M, Huang Z, Zang X, Pan L, Liang W,
Chen J, Qian H, Xu W, Jiang P and Zhang X: Long noncoding RNA
LINC00978 promotes cancer growth and acts as a diagnostic biomarker
in gastric cancer. Cell Prolif. 5:2017.doi: 10.1111/cpr.12425.
|
|
17
|
Zhang Z, Zhang Y, Sun XX, Ma X and Chen
ZN: microRNA-146a inhibits cancer metastasis by downregulating VEGF
through dual pathways in hepatocellular carcinoma. Mol Cancer.
14:52015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin
X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by
regulating ADAM10 and β-catenin pathway in hepatocellular
carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu S, Jing L, Yin XR, Wang MC, Chen YM,
Guo Y, Nan KJ and Han LL: MiR-195 suppresses the metastasis and
epithelial-mesenchymal transition of hepatocellular carcinoma by
inhibiting YAP. Oncotarget. 8:99757–99771. 2017.PubMed/NCBI
|
|
20
|
Yang L, Wei N, Wang L, Wang X and Liu QH:
miR-498 promotes cell proliferation and inhibits cell apoptosis in
retinoblastoma by directly targeting CCPG1. Childs Nerv Syst.
34:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matamala N, Vargas MT, González-Cámpora R,
Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras
A, Miñambres R, Martínez-Delgado B, et al: MicroRNA deregulation in
triple negative breast cancer reveals a role of miR-498 in
regulating BRCA1 expression. Oncotarget. 7:20068–20079. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chai C, Wu H, Wang B, Eisenstat DD and
Leng RP: MicroRNA- 498 promotes proliferation and migration by
targeting the tumor suppressor PTEN in breast cancer cells.
Carcinogenesis. 39:1185–1196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dai YH, Tang YP, Zhu HY, Lv L, Chu Y, Zhou
YQ and Huo JR: ZEB2 promotes the metastasis of gastric cancer and
modulates epithelial mesenchymal transition of gastric cancer
cells. Dig Dis Sci. 57:1253–1260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB,
He YL and Song XM: ZEB2 promotes tumor metastasis and correlates
with poor prognosis of human colorectal cancer. Am J Transl Res.
9:2838–2851. 2017.PubMed/NCBI
|
|
25
|
Chen Z, Zhang J, Zhang Z, Feng Z, Wei J,
Lu J, Fang Y, Liang Y, Cen J, Pan Y, et al: The putative tumor
suppressor microRNA-30a-5p modulates clear cell renal cell
carcinoma aggressiveness through repression of ZEB2. Cell Death
Dis. 8:e28592017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kan Q, Su Y and Yang H: MicroRNA-335 is
downregulated in papillary thyroid cancer and suppresses cancer
cell growth, migration and invasion by directly targeting ZEB2.
Oncol Lett. 14:7622–7628. 2017.PubMed/NCBI
|
|
27
|
Pang X, Huang K, Zhang Q, Zhang Y and Niu
J: miR-154 targeting ZEB2 in hepatocellular carcinoma functions as
a potential tumor suppressor. Oncol Rep. 34:3272–3279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu B, Sun M, Liu J, Hong G and Lin Q:
MicroRNA-204 suppressed proliferation and motility capacity of
human hepatocellular carcinoma via directly targeting zinc finger
E-box binding homeobox 2. Oncol Lett. 13:3823–3830. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion, and
apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou DD, Wang X, Wang Y, Xiang XJ, Liang
ZC, Zhou Y, Xu A, Bi CH and Zhang L: MicroRNA-145 inhibits hepatic
stellate cell activation and proliferation by targeting ZEB2
through Wnt/β-catenin pathway. Mol Immunol. 75:151–160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vasuri F, Visani M, Acquaviva G, Brand T,
Fiorentino M, Pession A, Tallini G, D'Errico A and de Biase D: Role
of microRNAs in the main molecular pathways of hepatocellular
carcinoma. World J Gastroenterol. 24:2647–2660. 2018. View Article : Google Scholar : PubMed/NCBI
|
